Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

Sales from new products (Jevtana® and Multaq®) totaled euro 111 million versus euro 24 million in Q1 2010.

Net sales for Jevtana® (cabazitaxel) were euro 48 million in the first quarter of 2011 mostly generated in the U.S. This new anti-cancer agent was launched in the U.S. in July 2010 for patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-based therapy. The patient share of Jevtana® in the U.S. in second line metastatic hormone-refractory prostate cancer reached 54% in February (IntrinsiQ February 2011). In March 2011, Jevtana® received marketing authorization from the European Commission. The first launch of Jevtana® in the EU occurred in Germany in April 2011.

First-quarter net sales of Multaq® were euro 63 million (versus euro 24 million in Q1 2010), of which euro 44 million was generated in the U.S. Sales in Western Europe reached euro 17 million in the period. In January 2011, sanofi-aventis issued a Dear Health Care Provider Letter worldwide. The FDA also issued a Drug Safety Communication on hepatic events reported in patients treated with Multaq®. The revised product information was updated accordingly. The benefit/risk assessment of Multaq® by the EMA is ongoing. In the U.S. Multaq® received new Tier 2 unrestricted status with two major Managed Care accounts (United Healthcare Medicare and Commercial).

Worldwide presence(1) of Plavix®/Iscover®

First-quarter worldwide presence of Plavix® was euro 1,734 million, up 0.4% impacted by generic competition in Europe. In the U.S., Plavix® sales were euro 1,200 million, up 7.2% (net sales consolidated by Bristol-Myers Squibb). The product continued its success in Japan and China with a sales increase of +28.8% (euro 139 million) and +31.1% (euro
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... BERWYN, Pa. , July 25, 2014  AMETEK, ... appointment of Kurtis L. Goos as Vice ... Engineered Materials, Interconnects and Packaging (EMIP) Division. ... has extensive general management and business development experience, especially ... to make important contributions to the continued growth and ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... Pediatrics, reacts to a recent study, which shows how grief ... - http://photos.prnewswire.com/prnh/20140723/129709 According to ... stress are more likely than others to grow up overweight ... There were two specific types of stress that ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... XTENT, Inc.,(Nasdaq: XTNT ) today announced a ... Notified Body for CE Mark approval of its ... that recently,presented six-month follow up results from the ... Agency, which reviews the drug formulation,submission of XTENT,s ...
... Make Qnexa the New Clinical Gold, Standard Drug ... Resources, WALTHAM, Mass., June 12 Decision Resources, ... on pharmaceutical and,healthcare issues, finds that a drug that ... would earn a 40 percent patient share in,the obesity ...
Cached Medicine Technology:XTENT Announces European Regulatory Update 2XTENT Announces European Regulatory Update 3A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market 2
(Date:7/25/2014)... July 25, 2014 DON’T PAUSE is a ... uncomfortable bloating, hot flashes, mood swings, burning tongue menopause ... Dr. Shoreh Ershadi. The AntiAging Institute of California is now ... allows women to try this revolutionary product. For a limited ... get a third bottle at no charge. , ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- Dietary changes can dramatically ... a daily basis, according to a new study. ... might help detect and ease flare-ups for people with ... colitis and Crohn,s disease), the researchers said. Trillions ... effect on human health isn,t well understood, the Massachusetts ...
(Date:7/25/2014)... San Francisco, Ca (PRWEB) July 25, 2014 ... in business with their Anniversary Futon Sale. The Futon Shop ... mom and pop shop, which has grown from a few ... States over 33 different kinds of futon mattresses. , ... mouth in the beginning and the desire to sleep on ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 In an election ... it’s no surprise that Americans may not be sleeping well, ... according to a new poll conducted by US-Mattress . ... from across the country, “Which Political Party Do You Side ... that those registered as Independents tout a higher rate of ...
(Date:7/25/2014)... the U.S. are living with a brain tumor, and ... factors, scientists are still searching for answers. , "Right ... and we don,t know why people develop brain tumors," ... Brain Tumor Association. "It,s frustrating for the brain tumor ... funds research to pursue answers to these questions, and ...
Breaking Medicine News(10 mins):Health News:AntiAging Institute of California Now Offers DON'T PAUSE for Menopause with a Special Promotion 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 3Health News:New Study Shows the Growing Number of Independent Voters Have a Greater Propensity for Sleeping Well vs. Democrats or Republicans 2Health News:New Study Shows the Growing Number of Independent Voters Have a Greater Propensity for Sleeping Well vs. Democrats or Republicans 3Health News:Brain tumor causes and risk factors elude scientists 2
... Amilpar,(BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and Reuters: ... today its consolidated,results for the fourth quarter 2007 ... financial information is presented on a consolidated basis,and ... Law and the,Accounts Chart of the Agencia Nacional ...
... 11 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Brothers Global Healthcare Conference on Wednesday, March 19,at ... a live webcast of,the presentation at:, http://cc.talkpoint.com/LEHM002/031808a_jw/default.asp?entity=OnyxPharmaceu ,tic ... on 15 minutes early in order to,register and ...
... new study in the,Journal of the American Medical ... (methicillin-resistant Staphylococus aureus), a simple,skin or nasal swab, ... Screening for Methicillin-Resistant Staphylococcus aureus at,Hospital Admission and ... 10, March 12, 2008)., The findings of ...
... 11 Eli Manning, NFL Most,Valuable Player 2008 ... New,York Giants, will address a National Press Club ... national challenge to encourage Americans to be,more active., ... the President,s Council on,Physical Fitness and Sports, Manning ...
... Inc.,(NYSE: RBN ) announced today that it will ... the period ended February 29, 2008, after,market close on ... conference,call will be held at 2:00 p.m., EDT on ... Chief Executive Officer, and Christopher M. Hix,Vice President and ...
... Center have teased out two distinct sets of risk ... are two completely different kinds of the disease. , ... caused by the human papillomavirus (HPV), a common sexually ... behaviors and marijuana use, rather than tobacco and alcohol. ...
Cached Medicine News:Health News:Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007 2Health News:JAMA Article Provides False Support for CDC's Do-Nothing Position on MRSA 2Health News:Researchers ID behavioral risk factors for head and neck cancers 2Health News:Researchers ID behavioral risk factors for head and neck cancers 3
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... is the newest real-time PCR instrument offered ... offers six detection channels that provide fluorescence ... and 710nm. Perform rapid PCR due to ... with glass capillaries. Virtually any published protocol ...
Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
... standard in QPCR with the Mx4000 multiplex ... superior performance, more flexibility, and reasonable pricing. ... with Windows 98SE and Pentium III (or ... Speakers, Surge Protector (US only), Mx4000 Software ...
Medicine Products: